PMID- 34403203
OWN - NLM
STAT- MEDLINE
DCOM- 20220510
LR  - 20220510
IS  - 1755-3768 (Electronic)
IS  - 1755-375X (Linking)
VI  - 100
IP  - 4
DP  - 2022 Jun
TI  - Prediction of anti-VEGF efficacy in diabetic macular oedema using intraocular 
      cytokines and macular optical coherence tomography.
PG  - e891-e898
LID - 10.1111/aos.15008 [doi]
AB  - PURPOSE: In eyes with diabetic macular oedema (DME), aqueous humour (AH) cytokine 
      levels before and after anti-vascular endothelial growth factor (VEGF) treatment 
      were compared and correlated with optical coherence tomography structural 
      parameters. METHODS: This prospective study included 56 control patients with 
      cataracts and 83 patients with DME manifesting as diffuse retinal thickening 
      (DRT), cystoid macular oedema and serous retinal detachment (SRD). AH samples 
      were obtained before intravitreal injection of anti-VEGF or cataract surgery. 
      VEGF, interleukin (IL)-6, IL-8, IL-10, interferon-inducible protein 10 (IP-10) 
      and monocyte chemotactic protein 1 (MCP-1) levels were measured by multiplex bead 
      assay. AH cytokine levels, central macular thickness (CMT), number of 
      hyper-reflective foci (HF), continuity of external limiting membrane and 
      ellipsoid zone (EZ) and best-corrected visual acuity were evaluated. RESULTS: In 
      SRD, IL-6 and MCP-1 levels and HF were increased (all p < 0.05) compared to DRT. 
      At baseline, the number of HF was correlated with VEGF, IL-6, IL-8, IP-10 and 
      MCP-1 (all p < 0.05). Eyes sensitive to anti-VEGF treatment had high baseline 
      levels of VEGF, MCP-1, HF and many EZ disruptions (all p < 0.05). DME patients 
      with normal VEGF levels but with high levels of IL-8, IP-10 and MCP-1 (all 
      p < 0.05) had little change in CMT after anti-VEGF treatment (p = 0.678). 
      CONCLUSIONS: AH concentrations of some inflammatory cytokines in DME were 
      differentially expressed among the three DME morphologies. HF was associated with 
      VEGF and other inflammatory cytokine levels. Multiple HF at baseline predicted a 
      significant decrease in CMT, and eyes with normal VEGF but increased inflammatory 
      cytokines may be insensitive to anti-VEGF treatment.
CI  - (c) 2021 Acta Ophthalmologica Scandinavica Foundation. Published by John Wiley & 
      Sons Ltd.
FAU - Mao, Jianbo
AU  - Mao J
AUID- ORCID: 0000-0002-5437-7749
AD  - Department of Retina Center, Affiliated Eye Hospital of Wenzhou Medical 
      University, Hangzhou, Zhejiang, China.
FAU - Zhang, Shian
AU  - Zhang S
AD  - Department of Retina Center, Affiliated Eye Hospital of Wenzhou Medical 
      University, Hangzhou, Zhejiang, China.
FAU - Zheng, Zicheng
AU  - Zheng Z
AD  - Department of Retina Center, Affiliated Eye Hospital of Wenzhou Medical 
      University, Hangzhou, Zhejiang, China.
FAU - Deng, Xinyi
AU  - Deng X
AD  - Department of Retina Center, Affiliated Eye Hospital of Wenzhou Medical 
      University, Hangzhou, Zhejiang, China.
FAU - Liu, Chenyi
AU  - Liu C
AD  - Chicago College of Optometry, Midwestern University, Downers Grove, IL, USA.
FAU - Chen, Yiqi
AU  - Chen Y
AD  - Department of Retina Center, Affiliated Eye Hospital of Wenzhou Medical 
      University, Hangzhou, Zhejiang, China.
FAU - Zhao, Shixin
AU  - Zhao S
AD  - Department of Retina Center, Affiliated Eye Hospital of Wenzhou Medical 
      University, Hangzhou, Zhejiang, China.
FAU - Zhang, Yun
AU  - Zhang Y
AD  - Department of Retina Center, Affiliated Eye Hospital of Wenzhou Medical 
      University, Hangzhou, Zhejiang, China.
FAU - Shen, Lijun
AU  - Shen L
AUID- ORCID: 0000-0002-7518-2932
AD  - Department of Retina Center, Affiliated Eye Hospital of Wenzhou Medical 
      University, Hangzhou, Zhejiang, China.
LA  - eng
PT  - Journal Article
DEP - 20210817
PL  - England
TA  - Acta Ophthalmol
JT  - Acta ophthalmologica
JID - 101468102
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Chemokine CXCL10)
RN  - 0 (Cytokines)
RN  - 0 (Interleukin-6)
RN  - 0 (Interleukin-8)
RN  - 0 (Vascular Endothelial Growth Factor A)
SB  - IM
MH  - Angiogenesis Inhibitors/therapeutic use
MH  - Chemokine CXCL10/therapeutic use
MH  - Cytokines/metabolism
MH  - *Diabetes Mellitus/drug therapy
MH  - *Diabetic Retinopathy/complications/diagnosis/drug therapy
MH  - Humans
MH  - Interleukin-6/metabolism
MH  - Interleukin-8
MH  - Intravitreal Injections
MH  - *Macular Edema/diagnosis/drug therapy/etiology
MH  - Prospective Studies
MH  - Tomography, Optical Coherence
MH  - Vascular Endothelial Growth Factor A/metabolism
MH  - Visual Acuity
OTO - NOTNLM
OT  - anti-VEGF
OT  - cytokine
OT  - diabetic macular oedema
OT  - hyper-reflective foci
OT  - optical coherence tomography
EDAT- 2021/08/18 06:00
MHDA- 2022/05/11 06:00
CRDT- 2021/08/17 12:35
PHST- 2021/04/22 00:00 [received]
PHST- 2021/08/04 00:00 [accepted]
PHST- 2021/08/18 06:00 [pubmed]
PHST- 2022/05/11 06:00 [medline]
PHST- 2021/08/17 12:35 [entrez]
AID - 10.1111/aos.15008 [doi]
PST - ppublish
SO  - Acta Ophthalmol. 2022 Jun;100(4):e891-e898. doi: 10.1111/aos.15008. Epub 2021 Aug 
      17.